GlassScriptPhysician profile
Patricia M Calhoun
NPI 1184601726
$13,494.61
in general payments reported to CMS, 2019-2025
53 companies · $1,970 in 2025
The $1,970 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,362 · 2020: $1,605 · 2021: $2,328 · 2022: $1,869 · 2023: $1,948 · 2024: $2,413 · 2025: $1,970.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,146 · Education: $185.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,146.06 |
| Education | $184.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,304.36 | 2019-2025 | Ubrelvy, Vraylar, Qulipta |
| Novo Nordisk INC | $1,210.11 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Pfizer INC. | $1,172.72 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,059.98 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Lilly USA, LLC | $1,031.01 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $947.10 | 2019-2024 | Shingrix, Arexvy, Bexsero |
| Merck Sharp & Dohme LLC | $712.10 | 2019-2025 | Capvaxive, Steglatro, Gardasil 9 |
| Astellas Pharma US INC | $698.73 | 2019-2024 | Myrbetriq, Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $667.07 | 2019-2025 | Jardiance, Ofev |
| Amgen INC. | $624.80 | 2019-2025 | Otezla, Repatha, Otezla |
| Abbott Laboratories | $586.86 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Amarin Pharma, INC. | $412.94 | 2019-2022 | |
| Phathom Pharmaceuticals, INC. | $364.96 | 2024-2025 | Voquezna |
| Janssen Pharmaceuticals, INC | $303.02 | 2020-2024 | Spravato, Xarelto |
| Eisai INC. | $237.06 | 2020-2025 |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patricia Calhoun listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.